Horton, C., LaDuca, H., Blanco, K., Lo, M., Speare, V., Dolinsky, J., Kurian, A. Shariff-Marco, S., Yang, J., John, E. M., Kurian, A. W., Cheng, I., Leung, R., Koo, J., Monroe, K. R., Henderson, B. E., Bernstein, L., Lu, Y., Kwan, M. L., Sposto, R., Vigen, C. L., Wu, A. H., Keegan, T. H., Gomez, S. L. Navigating choices when applying multiple imputation in the presence of multi-level categorical interaction effects. AYAs also were more likely to be diagnosed with stage III/IV disease and high-grade tumors than were older women. I was born in Kerala, India on 27 June 1989. Advances in bioinformatics also facilitate the interpretation of large amounts of genomic data. View details for DOI 10.1001/jamaoncol.2022.7146. Ethnic distribution of the population also influenced HER2-positive percentages. In this study, we developed a weak-supervision framework for breast cancer recurrence prediction in which we trained a deep learning model on a large sample of free-text clinic notes by utilizing a combination of manually curated labels and NLP-generated non-perfect recurrence labels. The accuracy of mammography and breast MRI was estimated from published data in high-risk women. hormone receptor-positive breast cancer. All gains were reduced with less than 100% treatment completion.The extension of endocrine therapy from 5 to 10years modestly improved lifetime breast cancer outcomes, but in some women, treatment-related adverse events may outweigh benefits. modalities in tumor cell lines. Four-year breast cancer-specific survival per molecular subtypes and clinical/demographic factors were calculated. Out of the total compensation, he received $800,000 as a salary, $3,612,553 as a bonus, $69,380,000 as stock options, and $7,337 from other types of compensation. Nine other genes were associated with a p-value, View details for DOI 10.1038/s42003-021-02990-6, Genome-wide association studies (GWAS) have identified multiple common breast cancer susceptibility variants. We examined whether accounting for racial/ethnic differences in the prevalence of clinical, patient, and lifestyle and contextual factors that are associated with breast cancer-specific mortality can explain this disparity.The California Breast Cancer Survivorship Consortium combined interview data from six California-based breast cancer studies with cancer registry data to create a large racially diverse cohort of women with primary invasive breast cancer. For your information, Thomas Kurian is a married man. The odds ratio (OR) per unit standard deviation was consistent between validations (OR, 1.45 [95% CI, 1.39 to 1.52]; OR 1.47 [95% CI, 1.45 to 1.49]). Causal inference analyses using the identified genetic variants indicate that extending reproductive life in women improves bone health and reduces risk of type 2 diabetes, but increases the risk of hormone-sensitive cancers. Yet, Asian Americans are more likely than other groups to have mastectomy or omit radiation after BCS.We applied polytomous logistic regression and recursive partitioning to analyze factors associated with mastectomy, or BCS without radiation, among 20,987 California Asian Americans diagnosed with stage 0 to II breast cancer from 1990 to 2007.The percentage receiving mastectomy ranged from 40% among U.S.-born Chinese to 58% among foreign-born Vietnamese. He led 35,000-people software development team in 32 countries with an R&D budget of $4 billion. There is also evidence that risks of prostate cancer and pancreatic cancer are elevated in these carriers. The results in MINDACT and Asian women from BCAC were consistent.An increased PRS313 is associated with favorable tumor characteristics, but is not independently associated with prognosis. Goodness-of-fit analysis compared expected with observed relative risks by quantiles of the MA-PRS distribution.In independent validation, the MA-PRS was significantly associated with BC risk in the full cohort (odds ratio, 1.43; 95% CI, 1.40 to 1.46; P = 8.6 10-308) and within each major ancestry. Former Oracle executive Thomas Kurian replaces Diane Greene, the current CEO of Google Cloud. For more information, please contact Charlene Kranz, (650) 498 - 7977. Challenges remain for the broad adoption of panel tests, some of which will be addressed by the accumulation of large public databases of annotated clinical variants. Other variables had negligible impact on disparity.While contextual, physical activity, body size, and comorbidity variables may influence breast cancer-specific mortality, they do not explain racial/ethnic mortality disparity.Other factors besides those investigated here may explain the existing racial/ethnic disparity in mortality. Use of the 21-gene recurrence score (RS) did not change among node-negative/micrometastasis patients, and increasing RS use in node-positive patients accounted for one-third of the chemotherapy decline. Yadav, S., Boddicker, N. J., Na, J., Polley, E. C., Hu, C., Hart, S. N., Gnanaolivu, R. D., Larson, N., Holtegaard, S., Huang, H., Dunn, C. A., Teras, L. R., Patel, A. V., Lacey, J. V., Neuhausen, S. L., Martinez, E., Haiman, C., Chen, F., Ruddy, K. J., Olson, J. E., John, E. M., Kurian, A. W., Sandler, D. P., O'Brien, K. M., Taylor, J. We investigated social disparities in breast cancer (BC) mortality, leveraging data from the California Breast Cancer Survivorship Consortium. Daly, M. B., Pilarski, R., Berry, M., Buys, S. S., Farmer, M., Friedman, S., Garber, J. E., Kauff, N. D., Khan, S., Klein, C., Kohlmann, W., Kurian, A., Litton, J. K., Madlensky, L., Merajver, S. D., Offit, K., Pal, T., Reiser, G., Shannon, K. M., Swisher, E., Vinayak, S., Voian, N. C., Weitzel, J. N., Wick, M. J., Wiesner, G. L., Dwyer, M., Darlow, S. Reply to Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'. B., John, E. M., Joseph, V. n., Konstantopoulou, I. n., Kurian, A. W., Kwong, A. n., Landucci, E. n., Lesueur, F. n., Loud, J. T., Machackova, E. n., Mai, P. L., Majidzadeh-A, K. n., Manoukian, S. n., Montagna, M. n., Moserle, L. n., Mulligan, A. M., Nathanson, K. L., Nevanlinna, H. n., Ngeow Yuen Ye, J. n., Nikitina-Zake, L. n., Offit, K. n., Olah, E. n., Olopade, O. I., Osorio, A. n., Papi, L. n., Park, S. K., Pedersen, I. S., Perez-Segura, P. n., Petersen, A. H., Pinto, P. n., Porfirio, B. n., Pujana, M. A., Radice, P. n., Rantala, J. n., Rashid, M. U., Rosenzweig, B. n., Rossing, M. n., Santamaria, M. n., Schmutzler, R. K., Senter, L. n., Simard, J. n., Singer, C. F., Solano, A. R., Southey, M. C., Steele, L. n., Steinsnyder, Z. n., Stoppa-Lyonnet, D. n., Tan, Y. Y., Teixeira, M. R., Teo, S. H., Terry, M. B., Thomassen, M. n., Toland, A. E., Torres-Esquius, S. n., Tung, N. n., van Asperen, C. J., Vega, A. n., Viel, A. n., Vierstraete, J. n., Wappenschmidt, B. n., Weitzel, J. N., Wieme, G. n., Yoon, S. Y., Zorn, K. K., McGuffog, L. n., Parsons, M. T., Hamann, U. n., Greene, M. H., Kirk, J. Most cases with MMR-D were endometrioid (n=11, 68.7%); (95% CI: 44.2%-86.1%). View details for DOI 10.1093/jncics/pkz062, View details for PubMedCentralID PMC7049983, View details for Web of Science ID 000608680100005, View details for DOI 10.1200/JCO.2019.37.27_suppl.34, View details for Web of Science ID 000518223100033, View details for Web of Science ID 000493066600021, View details for Web of Science ID 000467473000011, View details for DOI 10.1200/JCO.2019.37.15_suppl.1525, View details for Web of Science ID 000487345804321, View details for DOI 10.1200/JCO.2019.37.15_suppl.e12046, View details for Web of Science ID 000487345800040, View details for DOI 10.1200/JCO.2019.37.15_suppl.6531, View details for Web of Science ID 000487345806085, View details for Web of Science ID 000487345804287, View details for DOI 10.1200/JCO.2019.37.15_suppl.560, View details for Web of Science ID 000487345803553, View details for DOI 10.1200/JCO.2019.37.15_suppl.1513, View details for Web of Science ID 000487345804309, View details for DOI 10.1200/JCO.2019.37.15_suppl.3069, View details for Web of Science ID 000487345805003, View details for Web of Science ID 000461693200015, View details for DOI 10.1001/jamasurg.2018.4885, View details for Web of Science ID 000461900900023. Future research areas include randomized controlled trials, studies on specific cancer types in relation to statin use, studies on populations without clinical indication for statins, elucidation of underlying biological mechanisms, and investigation of different statin types. CDH1 mutations are an indication for total gastrectomy in these patients. Write CSS OR LESS and hit save. Breast Cancer Risk Reduction, Version 2.2015. [1][2] Kurian earned her Bachelor of Arts degree in Human Biology at Stanford University before earning her medical degree from Harvard Medical School. Carriers of a BRCA1/2 pathogenic or likely pathogenic variant have an excessive risk for both breast and ovarian cancer that warrants consideration of more intensive screening and preventive strategies. Here we evaluate the best performing PRSs for European-ancestry women using data from 17,262 breast cancer cases and 17,695 controls of Asian ancestry from 13 case-control studies, and 10,255 Chinese women from a prospective cohort (413 incident breast cancers). We examined racial differences in outcome according to subtype and stage in a diverse, population-based series of 103,498 patients.We obtained data for all invasive breast cancers diagnosed 1/1/2005-12/31/2012 and followed through 12/31/2012 among 93,760 non-Hispanic white and 9,738 African-American women in California. Lastly, we determined whether synergistic drug pairs found in the EHRs were enriched among synergistic drug pairs from gene-expression data using a method similar to gene set enrichment analysis.From EHRs, we discovered 3 drug-class pairs associated with lower mortality: anti-inflammatories and hormone antagonists, anti-inflammatories and lipid modifiers, and lipid modifiers and obstructive airway drugs. In a multivariable model, triple negative (RH 2.85, 95% CI 2.50-3.24) and HR-/HER2+ (RH 1.60, 95% CI 1.37-1.87) had worse, while HR+/HER2+ had similar, risk of all-cause death compared to HR+/HER2- breast cancer.De novo metastatic breast cancer was more likely to be HER2+. In this role, he drove a number of company-wide initiatives focused on transforming Oracle into an e-Business. A second opinion from a medical oncologist may facilitate decision making for women with breast cancer, yet little is known about second opinion use.To investigate the patterns and correlates of second opinion use and the effect on chemotherapy decisions.A total of 1901 women newly diagnosed with stages 0 to II breast cancer between July 2013 and September 2014 (response rate, 71.0%) were accrued through 2 population-based Surveillance, Epidemiology, and End Results registries (Georgia and Los Angeles County, California) and surveyed about their experiences with medical oncologists, decision making, and chemotherapy use.Factors associated with second opinion use were evaluated using logistic regression. View details for DOI 10.1007/s10549-016-4076-5, View details for Web of Science ID 000393023500014. View Original Notice Allison, Thomas "Tommy" Thomas Edward "Tommy" Allison, age 75, of Gr We calculated frequencies of breast cancer subtypes among Asian ethnic groups and evaluated their associations with clinical and demographic factors. The role of prophylactic versus therapeutic gastrectomy for HDGC was studied prospectively.Eighteen consecutive patients with CDH1 mutations and positive family history were studied prospectively, including 13 without and 5 with symptoms.
Stephenson County Accident Reports,
Did Tula Pink Lose Weight,
Articles T